Make the profile of
BigOmics Analytics SA yours.

Company description

BigOmics Analytics is a Swiss life sciences software company dedicated to democratizing omics data analysis. Founded in 2018 as a spin-off of the Institute of Oncology Research in Switzerland, BigOmics develops interactive, user-friendly platforms that empower biologists and bioinformaticians to visualize, analyze, and understand their omics data in minutes rather than weeks or months. The company's flagship product, Omics Playground, serves over 4,000 life scientists worldwide across more than 50 biotech and pharma companies and academic institutions, accelerating the transition to data-driven precision medicine.

BigOmics was founded by Ivo Kwee and Murodzhon Akhmedov, won third prize in the StartCup Ticino competition for its vision to democratize big data analysis in life science research, and has raised a total of CHF 2.7 million in funding. Its mission is to make advanced omics analysis accessible to everyone — enabling faster discoveries and more confident scientific decisions.

Omics Playground — Core Platform

• A single, integrated software platform supporting both RNA-Seq data analysis and Proteomics data analysis
• Designed to be intuitive and easy to use for both biologists and bioinformaticians
• Delivers robust and reproducible results using best-in-class methods and algorithms at every analysis step
• Reduces time spent on data analysis and handover, freeing up more time for scientific discovery
• Enables fast and interactive collaboration between research teams, with a reported 75% increase in collaboration effectiveness

Key Features and Analytical Capabilities

• 18+ analysis modules covering a broad range of omics workflows
• 150+ interactive plots for flexible and comprehensive data visualization
• Co-analysis with 6,000+ public datasets to contextualize experimental findings
• Access to 50,000+ public gene sets and pathways, including GO, Reactome, Hallmark, and MSigDB
• Drug connectivity and drug sensitivity databases featuring 30,000+ drug expression profiles
• Data is analytics-ready within minutes of upload, dramatically reducing time-to-insight

Demonstrated Business and Scientific Impact

• 82% time saved in data handover processes
• 8x faster analysis compared to traditional approaches
• 92% ROI reported by customers
• 76% improvement in Decision Confidence Index, enabling scientists to trust and act on their results
• Recognized by senior scientists at organizations such as Valerio Therapeutics as providing the most trustworthy results among evaluated solutions
• Supports ongoing and iterative data analysis requests without requiring repeated manual effort from bioinformaticians

Customers and Deployment

• Trusted by over 50 biotech and pharma companies and research institutions worldwide
• Supports academic research institutes as well as enterprise life sciences organizations
• Used by both individual scientists and collaborative research teams requiring shared access to omics insights
• Launched commercially in 2019, with continued growth and enterprise adoption following its CHF 2.7M funding round in 2021

BigOmics Analytics continues to expand its platform and user base with the goal of enabling omics data analysis at scale — helping life scientists fast-track their discovery processes and ultimately contributing to a world free of cancer and complex diseases.

AI-generated · replace with your own

Software attributed to BigOmics Analytics SA

• Omics PlaygroundView
• Omics Playground - RNA-Seq Data AnalysisView
• Omics Playground - Multi-Omics Add-onView

Edit all with premium access